Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT05440760 · ClinicalTrials.gov registry record · NA
Using Virtual Reality Technology to Improve Patient Experience and Quality of Care During Brachytherapy
A NA study of Endocervical Cancer, sponsored by University of Arkansas.
- Recruiting
- Registry status
- NA
- Development phase
- 20
- Enrollment target
- 1
- Study location
NCT05440760 is a NA study of Endocervical Cancer that is actively recruiting participants, run by University of Arkansas. The registered enrollment target is 20 participants. The trial reports 1 study location across 1 state.
The verdict
NCT05440760, a NA study of Endocervical Cancer, is actively recruiting participants, sponsored by University of Arkansas.
- RECRUITING
- Registry status
- NA
- Development phase
- 20 participants
- Enrollment target
- 1
- Study location
Study Summary
The primary objective is to demonstrate the feasibility of incorporating VR distraction into the brachytherapy and radiotherapy clinical workflow. The secondary objective is to determine if VR distraction during brachytherapy treatment for cervical cancer improves subjects' satisfaction, procedural/acute pain, and need for analgesics or anxiolytics.
Conditions Studied
Interventions
- DEVICE The Oculus Quest 2 Virtual Reality Headset
Study Locations (1)
Arkansas
- University of Arkansas for Medical Sciences - Little Rock
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 20 participants |
| Start Date | 2022-08-08 |
| Est. Completion | 2027-12 |
| Phase | NA |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT05440760
The ClinicalTrials.gov registry entry for NCT05440760 describes a study currently listed as recruiting, categorized as NA. The registered enrollment target is 20 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is University of Arkansas, which has 318 total studies on file at ClinicalTrials.gov.
The record links to 1 condition, with Endocervical Cancer appearing as the primary indexed condition, and to 1 intervention - of which The Oculus Quest 2 Virtual Reality Headset is the first listed.
NCT05440760 reports 1 study location spanning 1 distinct geographic area - top geographies include Arkansas.
Frequently Asked Questions
What is clinical trial NCT05440760 about?
NCT05440760 is a clinical study titled "Using Virtual Reality Technology to Improve Patient Experience and Quality of Care During Brachytherapy". The primary objective is to demonstrate the feasibility of incorporating VR distraction into the brachytherapy and radiotherapy clinical workflow. The secondary objective is to determine if VR distraction during brachytherapy treatment for cervical cancer improves subjects' satisfaction, procedural...
What is the current status of trial NCT05440760?
This trial is currently recruiting. It is a NA study. The enrollment target is 20 participants. The study started on 2022-08-08. Estimated completion is 2027-12.
What conditions does trial NCT05440760 study?
This clinical trial studies the following conditions: Endocervical Cancer.
What interventions are being tested in trial NCT05440760?
The interventions under investigation include: The Oculus Quest 2 Virtual Reality Headset (DEVICE).
Who is sponsoring clinical trial NCT05440760?
This trial is sponsored by University of Arkansas, which has 318 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT05440760 being conducted?
This trial has 1 study location across Arkansas. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Endocervical Cancer
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
Study of NGM831 as Monotherapy and in Combination With Pembrolizumab or Pembrolizumab and NGM438 in Advanced or Metastatic Solid Tumors
ACTIVE NOT RECRUITING · Phase 1
-
Study of NGM438 as Monotherapy and in Combination With Pembrolizumab in Advanced or Metastatic Solid Tumors
ACTIVE NOT RECRUITING · Phase 1
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.